ProShare Advisors’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$15.7M Sell
249,935
-56,234
-18% -$4.5M 0.02% 301
2025
Q4
$29.2M Buy
306,169
+26,021
+9% +$2.55M 0.05% 251
2025
Q3
$27.4M Sell
280,148
-6,577
-2% -$681K 0.06% 249
2025
Q2
$30.8M Buy
286,725
+49,430
+21% +$5M 0.06% 241
2025
Q1
$23.9M Buy
237,295
+12,415
+6% +$1.25M 0.05% 251
2024
Q4
$20.1M Buy
224,880
+24,022
+12% +$2.11M 0.05% 254
2024
Q3
$16.8M Sell
200,858
-15,181
-7% -$1.2M 0.04% 268
2024
Q2
$16.6M Buy
216,039
+16,430
+8% +$1.2M 0.04% 259
2024
Q1
$13.7M Sell
199,609
-5,219
-3% -$336K 0.04% 280
2023
Q4
$11.8M Sell
204,828
-19,838
-9% -$1.06M 0.04% 285
2023
Q3
$11.9M Sell
224,666
-5,763
-3% -$302K 0.04% 282
2023
Q2
$12.5M Buy
230,429
+9,002
+4% +$470K 0.04% 280
2023
Q1
$11.1M Buy
221,427
+27,488
+14% +$1.3M 0.03% 290
2022
Q4
$8.97M Sell
193,939
-5,469
-3% -$237K 0.03% 328
2022
Q3
$7.72M Sell
199,408
-22,700
-10% -$911K 0.03% 332
2022
Q2
$8.28M Sell
222,108
-84,707
-28% -$3.45M 0.03% 374
2022
Q1
$13.6M Sell
306,815
-8,600
-3% -$373K 0.03% 306
2021
Q4
$13.4M Buy
315,415
+69,892
+28% +$2.94M 0.03% 311
2021
Q3
$10.7M Buy
245,523
+350
+0.1% +$15.5K 0.03% 328
2021
Q2
$10.5M Buy
245,173
+40,583
+20% +$1.71M 0.03% 359
2021
Q1
$7.91M Sell
204,590
-9,375
-4% -$355K 0.02% 400
2020
Q4
$7.69M Buy
213,965
+18,901
+10% +$681K 0.03% 384
2020
Q3
$7.45M Sell
195,064
-21,488
-10% -$828K 0.03% 336
2020
Q2
$7.6M Buy
216,552
+1,135
+0.5% +$40.9K 0.04% 307
2020
Q1
$7.03M Sell
215,417
-45,131
-17% -$1.76M 0.05% 302
2019
Q4
$11.8M Buy
260,548
+33,951
+15% +$1.42M 0.05% 325
2019
Q3
$9.22M Buy
226,597
+10,033
+5% +$425K 0.05% 332
2019
Q2
$9.31M Sell
216,564
-34,672
-14% -$1.33M 0.06% 316
2019
Q1
$9.64M Buy
251,236
+9,070
+4% +$346K 0.06% 291
2018
Q4
$8.56M Buy
242,166
+10,511
+5% +$381K 0.06% 256
2018
Q3
$8.92M Sell
231,655
-17,608
-7% -$615K 0.06% 252
2018
Q2
$8.15M Sell
249,263
-13,114
-5% -$396K 0.05% 273
2018
Q1
$7.17M Buy
262,377
+8,788
+3% +$239K 0.05% 343
2017
Q4
$6.29M Buy
253,589
+98,613
+64% +$2.72M 0.04% 379
2017
Q3
$4.52M Buy
154,976
+22,200
+17% +$613K 0.04% 393
2017
Q2
$3.68M Sell
132,776
-3,454
-3% -$91.7K 0.04% 419
2017
Q1
$3.39M Buy
136,230
+1,602
+1% +$39K 0.04% 427
2016
Q4
$2.91M Buy
134,628
+26,018
+24% +$568K 0.03% 453
2016
Q3
$2.58M Sell
108,610
-55,155
-34% -$1.32M 0.04% 418
2016
Q2
$3.83M Buy
163,765
+4,028
+3% +$87.1K 0.05% 296
2016
Q1
$3M Sell
159,737
-76,716
-32% -$1.35M 0.04% 342
2015
Q4
$4.36M Buy
236,453
+12,261
+5% +$220K 0.05% 314
2015
Q3
$3.68M Buy
224,192
+10,121
+5% +$173K 0.05% 326
2015
Q2
$3.79M Sell
214,071
-34,896
-14% -$624K 0.05% 336
2015
Q1
$4.42M Sell
248,967
-22,314
-8% -$353K 0.05% 336
2014
Q4
$3.59M Buy
271,281
+43,249
+19% +$553K 0.04% 399
2014
Q3
$2.69M Sell
228,032
-23,294
-9% -$293K 0.04% 553
2014
Q2
$3.21M Sell
251,326
-20,877
-8% -$271K 0.04% 468
2014
Q1
$3.68M Sell
272,203
-6,512
-2% -$85.5K 0.05% 382
2013
Q4
$3.35M Buy
278,715
+115,407
+71% +$1.36M 0.05% 478
2013
Q3
$1.92M Sell
163,308
-64,765
-28% -$701K 0.05% 428
2013
Q2
$2.11M Buy
+228,073
New +$1.93M 0.04% 436

Other funds holding BSX

ProShare Advisors's BSX Position: Q1 2026 in Review

ProShare Advisors reduced its Boston Scientific (BSX) stake by 18% in Q1 2026, selling an estimated $4.5M and leaving 249,935 shares worth $15.7M. The position accounts for 0.02% of the portfolio, ranked #301.

ProShare Advisors first reported a position in BSX in Q2 2013 and has held it in 52 quarters since. The position peaked at $30.8M in Q2 2025. 1,666 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • ProShare Advisors held 249,935 shares of Boston Scientific worth $15.7M as of Q1 2026.
  • ProShare Advisors sold 56,234 Boston Scientific shares in Q1 2026, an estimated $4.5M.
  • Boston Scientific made up 0.02% of ProShare Advisors's portfolio in Q1 2026, its #301 holding.
  • ProShare Advisors first reported a position in Boston Scientific in Q2 2013 and has held it in 52 quarters since.
  • ProShare Advisors's Boston Scientific position peaked at $30.8M in Q2 2025.
  • 1,666 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.